William Blair Believes Quidel Corp (NASDAQ: QDEL) Still Has Room to Grow

By Jason Carr

William Blair analyst Brian Weinstein reiterated a Buy rating on Quidel Corp (NASDAQ: QDEL) yesterday. The company’s shares closed yesterday at $55.77, close to its 52-week high of $56.08.

Weinstein has an average return of 3.0% when recommending Quidel Corp.

According to TipRanks.com, Weinstein is ranked #1376 out of 4771 analysts.

Currently, the analyst consensus on Quidel Corp is Strong Buy and the average price target is $62.40, representing an 11.9% upside.

In a report issued on April 2, Barclays also maintained a Buy rating on the stock with a $63 price target.

The company has a one-year high of $56.08 and a one-year low of $22.44. Currently, Quidel Corp has an average volume of 363.4K.

Based on the recent corporate insider activity of 93 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of QDEL in relation to earlier this year. Most recently, in February 2018, Kenneth Buechler, a Director at QDEL bought 12,154 shares for a total of $197,503.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Quidel Corp. engages in the development, manufacture, and market of rapid diagnostic testing solutions. Its portfolio includes immunoassays, molecular, virology, and specialty products. Immunoassay tests are for physician offices, hospital laboratories, emergency departments, pharmacies, and other urgent care or alternative site settings.